Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 43291-43293 [E7-15149]

Download as PDF 43291 Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. Proposed Project: Substance Abuse Prevention and Treatment Block Grant Synar Report Format, FFY 2008–2010— (OMB No. 0930–0222)—Revision Section 1926 of the Public Health Service Act [42 U.S.C. 300x–26] stipulates that funding Substance Abuse Prevention and Treatment (SAPT) Block Grant agreements for alcohol and drug abuse programs for fiscal year 1994 and subsequent fiscal years require States to have in effect a law providing that it is unlawful for any manufacturer, retailer, or distributor of tobacco products to sell or distribute any such product to any individual under the age of 18. This section further requires that States approved by OMB under control number 0930–0163, and require that each State submit an annual Synar report to the Secretary describing their progress in complying with section 1926 of the PHS Act. The Synar report, due December 31 following the fiscal year for which the State is reporting, describes the results of the inspections and the activities carried out by the State to enforce the required law; the success the State has achieved in reducing the availability of tobacco products to individuals under the age of 18; and the strategies to be utilized by the State for enforcing such law during the fiscal year for which the grant is sought. SAMHSA’s Center for Substance Abuse Prevention will request OMB approval of revisions to the current report format associated with section 1926 (42 U.S.C. 300x–26). The report format is changing significantly. Any changes in either formatting or content are being made to simplify the reporting process for the States and to clarify the information as the States report it; both outcomes will facilitate consistent, credible, and efficient monitoring of Synar compliance across the States and will reduce the reporting burden by the States. All of the information required in the new report format is already being collected by the States. conduct annual, random, unannounced inspections to ensure compliance with the law; that the State submit annually a report describing the results of the inspections, describing the activities carried out by the State to enforce the required law, describing the success the State has achieved in reducing the availability of tobacco products to individuals under the age of 18, and describing the strategies to be utilized by the State for enforcing such law during the fiscal year for which the grant is sought. Before making an award to a State under the SAPT Block Grant, the Secretary must make a determination that the State has maintained compliance with these requirements. If a determination is made that the State is not in compliance, penalties shall be applied. Penalties ranged from 10 percent of the Block Grant in applicable year 1 (FFY 1997 SAPT Block Grant Applications) to 40 percent in applicable year 4 (FFY 2000 SAPT Block Grant Applications) and subsequent years. Respondents include the 50 States, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, the Commonwealth of the Northern Mariana Islands, Palau, Micronesia, and the Marshall Islands. Regulations that implement this legislation are at 45 CFR 96.130, are ANNUAL REPORTING BURDEN Responses per respondents Number of respondents1 45 CFR citation Hours per response Total hour burden Annual Report (Section 1—States and Territories) 96.130(e)(1–3) ................ State Plan (Section II–States and Territories) 96.130(e)(4,5)96.130(g) ......... 59 59 1 1 15 3 885 177 Total .......................................................................................................... 59 ........................ ........................ 1,062 mstockstill on PROD1PC66 with NOTICES 1 Red Lake Indian Tribe is not subject to tobacco requirements. Written comments and recommendations concerning the proposed information collection should be sent by September 4, 2007 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202–395– 6974. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: July 31, 2007. Elaine Parry, Acting Director, Office of Program Services. [FR Doc. E7–15143 Filed 8–2–07; 8:45 am] SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines BILLING CODE 4162–20–P VerDate Aug<31>2005 18:17 Aug 02, 2007 Jkt 211001 Substance Abuse and Mental Health Services Administration Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. E:\FR\FM\03AUN1.SGM 03AUN1 mstockstill on PROD1PC66 with NOTICES 43292 Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http:// www.workplace.samhsa.gov and http:// www.drugfreeworkplace.gov. FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276– 2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100– 71. Subpart C of the Mandatory Guidelines, ‘‘Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,’’ sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards. In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840/800–877–7016. (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290– 1150. Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 615–255– 2400. (Formerly: Aegis Analytical Laboratories, Inc.). Baptist Medical Center-Toxicology Laboratory, 9601 I–630, Exit 7, Little VerDate Aug<31>2005 18:17 Aug 02, 2007 Jkt 211001 Rock, AR 72205–7299, 501–202–2783. (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917. Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 239–561–8200/800–735–5416. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281. DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215–674–9310. Dynacare Kasper Medical Laboratories*, 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451–3702/800–661–9876. ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609. Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630. Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504–361–8989/800–433–3823. (Formerly: Laboratory Specialists, Inc.). Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130. (Formerly: Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986. (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919– 572–6900/800–833–3984. (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 13112 Evening Creek Drive, Suite 100, San Diego, CA 92128, 858– 668–3710/800–882–7272. (Formerly: Poisonlab, Inc.). Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, Seattle, WA 98122, 206–923–7020/800– 898–0180. (Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of Pathology PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 of Seattle, Inc.; DrugProof, Division of Laboratory of Pathology of Seattle, Inc.). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233– 6339. (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/ National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845. (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.). Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389– 3734/800–331–3734. MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700. (Formerly: NOVAMANN (Ontario), Inc.). MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244. Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608–267–6225. (Formerly: General Medical Laboratories). MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295 / 800–950–5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350– 3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774. (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Oregon Medical Laboratories, 123 International Way, Springfield, OR 97477, 541–341–8092. Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942. (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/ 800–541–7891x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643–5555. Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372/800–821–3627. Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590/800–729–6432. E:\FR\FM\03AUN1.SGM 03AUN1 mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216. (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 866– 370–6699/818–989–2521, (Formerly: SmithKline Beecham Clinical Laboratories). S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505–727–6300/800–999–5227. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x276. Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800– 279–0027. Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–364–7400. (Formerly: St. Lawrence Hospital & Healthcare System). St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305– 593–2260. US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085. *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that VerDate Aug<31>2005 18:17 Aug 02, 2007 Jkt 211001 43293 DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR 19644). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. DEPARTMENT OF THE INTERIOR Elaine Parry, Acting Director, Office of Program Services, SAMHSA. [FR Doc. E7–15149 Filed 8–2–07; 8:45 am] SUMMARY: In accordance with the provisions of the Rocky Flats National Wildlife Refuge Act of 2001 (Pub. L. 107–107, 115 Stat. 1012, 1380–1387) hereinafter referred to as the ‘‘Refuge Act,’’ the Secretary of Energy has transferred primary administrative jurisdiction over approximately 3,953.03 acres of real property at the former Rocky Flats Environmental Technology Site (RFETS), Jefferson and Boulder Counties, Colorado, to the Secretary of the Interior. Pursuant to section 3177(d) of the ‘‘Refuge Act,’’ the Secretary of the Interior hereby provides notice of the establishment of the Rocky Flats National Wildlife Refuge (Refuge). The ‘‘Refuge Act’’ provides that following environmental remediation of RFETS, under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, and other applicable provisions of law, the Secretary of Energy shall transfer administrative jurisdiction over real property comprising the Refuge to the Secretary of the Interior for establishment of the Rocky Flats National Wildlife Refuge. Environmental remediation of the Rocky Flats National Priorities List Site has been completed, except for on-going operations and maintenance, pursuant to a Record of Decision signed by the Department of Energy, Environmental Protection Agency (EPA) and the State of Colorado in 2006. On May 25, 2007, the Regional Administrator of the EPA published notice in the Federal Register announcing deletion of the Peripheral Operable Unit and Operable Unit 3. On June 11, 2007, the Administrator of the EPA, acting through the Regional Administrator, Region 8, EPA, certified to the Secretary of Energy and the Secretary of the Interior that all response actions for the deleted areas have been completed, except for the operation and maintenance associated with response acting and that all response actions are operating properly and successfully. Pursuant to the ‘‘Refuge Act,’’ administrative jurisdictions over portions of the deleted Peripheral Operable Unit, totaling approximately BILLING CODE 4160–20–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5125–N–31] Federal Property Suitable as Facilities To Assist the Homeless Office of the Assistant Secretary for Community Planning and Development, HUD. ACTION: Notice. AGENCY: SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless. EFFECTIVE DATE: August 3, 2007. FOR FURTHER INFORMATION CONTACT: Kathy Ezzell, Department of Housing and Urban Development, Room 7262, 451 Seventh Street, SW., Washington, DC 20410; telephone (202) 708–1234; TTY number for the hearing- and speech-impaired (202) 708–2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1–800–927–7588. SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in National Coalition for the Homeless v. Veterans Administration, No. 88–2503–OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today’s Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week. Dated: July 26, 2007. Mark R. Johnston, Deputy Assistant Secretary for Special Needs. [FR Doc. E7–14706 Filed 8–2–07; 8:45 am] BILLING CODE 4210–67–P PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 Fish and Wildlife Service Establishment of Rocky Flats National Wildlife Refuge, Colorado Fish and Wildlife Service, Interior. ACTION: Establishment of Rocky Flats National Wildlife Refuge. AGENCY: E:\FR\FM\03AUN1.SGM 03AUN1

Agencies

[Federal Register Volume 72, Number 149 (Friday, August 3, 2007)]
[Notices]
[Pages 43291-43293]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15149]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories Which Meet Minimum Standards To 
Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the laboratories currently certified to meet the 
standards of Subpart C of the Mandatory Guidelines for Federal 
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory 
Guidelines were first published in the Federal Register on April 11, 
1988 (53 FR 11970), and subsequently revised in the Federal Register on 
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on 
April 13, 2004 (69 FR 19644).
    A notice listing all currently certified laboratories is published 
in the Federal Register during the first week of each month. If any 
laboratory's certification is suspended or revoked, the laboratory will 
be omitted from subsequent lists until such time as it is restored to 
full certification under the Mandatory Guidelines.

[[Page 43292]]

    If any laboratory has withdrawn from the HHS National Laboratory 
Certification Program (NLCP) during the past month, it will be listed 
at the end, and will be omitted from the monthly listing thereafter.
    This notice is also available on the Internet at http://
www.workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, 
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke 
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in 
accordance with Executive Order 12564 and section 503 of Pub. L. 100-
71. Subpart C of the Mandatory Guidelines, ``Certification of 
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets 
strict standards that laboratories must meet in order to conduct drug 
and specimen validity tests on urine specimens for Federal agencies. To 
become certified, an applicant laboratory must undergo three rounds of 
performance testing plus an on-site inspection. To maintain that 
certification, a laboratory must participate in a quarterly performance 
testing program plus undergo periodic, on-site inspections.
    Laboratories which claim to be in the applicant stage of 
certification are not to be considered as meeting the minimum 
requirements described in the HHS Mandatory Guidelines. A laboratory 
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
    In accordance with Subpart C of the Mandatory Guidelines dated 
April 13, 2004 (69 FR 19644), the following laboratories meet the 
minimum standards to conduct drug and specimen validity tests on urine 
specimens:

    ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory).
    ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 
14624, 585-429-2264.
    Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, 
Memphis, TN 38118, 901-794-5770/888-290-1150.
    Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 
615-255-2400. (Formerly: Aegis Analytical Laboratories, Inc.).
    Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, 
Little Rock, AR 72205-7299, 501-202-2783. (Formerly: Forensic 
Toxicology Laboratory Baptist Medical Center).
    Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 
800-445-6917.
    Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort 
Myers, FL 33913, 239-561-8200/800-735-5416.
    Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 
229-671-2281.
    DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 
18974, 215-674-9310.
    Dynacare Kasper Medical Laboratories*, 10150-102 St., Suite 200, 
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702/800-661-9876.
    ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 
38655, 662-236-2609.
    Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, 
Canada N6A 1P4, 519-679-1630.
    Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 
70053, 504-361-8989/800-433-3823. (Formerly: Laboratory Specialists, 
Inc.).
    Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, 
VA 23236, 804-378-9130. (Formerly: Scientific Testing Laboratories, 
Inc.; Kroll Scientific Testing Laboratories, Inc.).
    Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288/800-800-2387.
    Laboratory Corporation of America Holdings, 69 First Ave., Raritan, 
NJ 08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical 
Laboratories, Inc.).
    Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly: 
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, 
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical 
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche 
Group).
    Laboratory Corporation of America Holdings, 13112 Evening Creek 
Drive, Suite 100, San Diego, CA 92128, 858-668-3710/800-882-7272. 
(Formerly: Poisonlab, Inc.).
    Laboratory Corporation of America Holdings, 550 17th Ave., Suite 
300, Seattle, WA 98122, 206-923-7020/800-898-0180. (Formerly: 
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; 
Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of 
Laboratory of Pathology of Seattle, Inc.).
    Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
    LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, 
KS 66219, 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.).
    Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North 
Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734.
    MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON, 
Canada L5N 2L8, 905-817-5700. (Formerly: NOVAMANN (Ontario), Inc.).
    MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 
55112, 651-636-7466/800-832-3244.
    Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608-
267-6225. (Formerly: General Medical Laboratories).
    MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295 / 800-950-5295.
    Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
    National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
    One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, 
Pasadena, TX 77504, 888-747-3774. (Formerly: University of Texas 
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology 
Laboratory).
    Oregon Medical Laboratories, 123 International Way, Springfield, OR 
97477, 541-341-8092.
    Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
    Pathology Associates Medical Laboratories, 110 West Cliff Dr., 
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
    Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 
858-643-5555.
    Physicians Reference Laboratory, 7800 West 110th St., Overland 
Park, KS 66210, 913-339-0372/800-821-3627.
    Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 
30340, 770-452-1590/800-729-6432.

[[Page 43293]]

(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-
Science Laboratories).
    Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 
19403, 610-631-4600/877-642-2216. (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
    Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 
91405, 866-370-6699/818-989-2521, (Formerly: SmithKline Beecham 
Clinical Laboratories).
    S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 
87109, 505-727-6300/800-999-5227.
    South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x276.
    Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
    Sparrow Health System, Toxicology Testing Center, St. Lawrence 
Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400. (Formerly: 
St. Lawrence Hospital & Healthcare System).
    St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., 
Oklahoma City, OK 73101, 405-272-7052.
    Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.
    Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 
33166, 305-593-2260.
    US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson 
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
    *The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 13, 2004 (69 FR 19644). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
 [FR Doc. E7-15149 Filed 8-2-07; 8:45 am]
BILLING CODE 4160-20-P